citalopram has been researched along with (2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bronson, JJ; Davis, CD; Gillman, KW; Lelas, S; Li, YW; Lodge, NJ; Macor, JE; Molski, TF; Newberry, KS; Newton, AE; Parker, MF; Pieschl, RL; Taber, MT; Wallace-Boone, TL | 1 |
1 other study(ies) available for citalopram and (2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine
| Article | Year |
|---|---|
NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
Topics: Animals; Antidepressive Agents; Aprepitant; Citalopram; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Gerbillinae; HEK293 Cells; Humans; Immobility Response, Tonic; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Piperidines; Prefrontal Cortex; Radioligand Assay; Receptors, Neurokinin-1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2013 |